Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership

This article was originally published in The Pink Sheet Daily

Executive Summary

The creatively structured deal adds Amylin’s GLP-1 franchise and other assets to the two pharmas’ diabetes portfolio.

Advertisement

Related Content

Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge
AstraZeneca Hopes Bydureon Pen Will Rewrite GLP-1 Story
Lilly Brings Non-Inferiority Data To GLP-1 Show Down
FDA Goes To Committee With Uncertainty About Metreleptin Efficacy For Partial Lipodystrophy
Diabetes Leaders Lilly, Sanofi Give A Glimpse Of GLP-1 Strategy
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
Dapagliflozin Faces Ominous Prospect Of New Trials
Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation
AstraZeneca Takes Out Antibiotic Firm Novexel, With Cash Back from Forest
BMS Deals Diabetes Drugs, Solidifies Specialist Stance

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel